GWO XI STEM CELL APPLIED TECHNOLOGY CO. , LTD Gwo Xi Stem Cell Applied Technology Co. , Ltd Share Price
Equities
6704
TW0006704000
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.65 TWD | +0.39% |
|
+13.18% | +6.47% |
| Sales 2022 | 181M 5.62M 442M | Sales 2023 | 141M 4.39M 345M | Capitalization | 3.48B 108M 8.52B |
|---|---|---|---|---|---|
| Net income 2022 | -112M -3.48M -274M | Net income 2023 | -88M -2.74M -215M | EV / Sales 2022 * | - |
| Net Debt 2022 | 358M 11.13M 876M | Net Debt 2023 | 14.55M 452K 35.59M | EV / Sales 2023 | 24.8 x |
| P/E ratio 2022 * |
-
| P/E ratio 2023 |
-37
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99% |
More Fundamentals
* Assessed data
| 1 day | +0.39% | ||
| 1 week | +13.18% | ||
| Current month | +24.28% | ||
| 1 month | +25.69% | ||
| 3 months | +16.59% | ||
| 6 months | +7.51% | ||
| Current year | +6.47% |
1 week
33.50
39.20
1 month
28.8039.20
Current year
28.6039.20
1 year
28.6053.30
3 years
28.6055.80
5 years
28.6055.80
10 years
28.6055.80
| Managers | Title | Age | Since |
|---|---|---|---|
Ming Hsi Chuang
CEO | Chief Executive Officer | - | 30/06/13 |
Pang Yu Li
DFI | Director of Finance/CFO | - | 31/05/21 |
Po Cheng Lin
CTO | Chief Tech/Sci/R&D Officer | - | 31/08/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Li Hsing Ho
BRD | Director/Board Member | - | 28/06/22 |
Nuan Hsuan Ho
BRD | Director/Board Member | - | 28/06/22 |
Ming Hsi Chuang
CEO | Chief Executive Officer | - | 30/06/13 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/05/24 | 38.65 | +0.39% | 566,743 |
| 16/05/24 | 38.5 | +0.65% | 637,155 |
| 15/05/24 | 38.25 | +2.41% | 682,637 |
| 14/05/24 | 37.35 | +9.37% | 1,054,597 |
| 13/05/24 | 34.15 | 0.00% | 97,113 |
End-of-day quote Taipei Exchange, May 16, 2024
More quotes
Gwo Xi Stem Cell Applied Technology Co Ltd is a Taiwan-based company mainly engaged in the development of stem cell drugs and technologies for the treatment of refractory diseases. The Company owns the Medical-Grade Cell Preparation Platform for the collection, isolation, culture, scaling up, packaging, testing, transportation, storage and treatment of human stem cells. The platform is modularized to create the stem cell activation technology Nigiro-Med, medical grade stem cell storage service and clinical cell preparation quality testing service. The Company operates through Stem Cell Freezing segment, Health Care Products and Maintenance Products segment, and Other segment.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +6.47% | 115M | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- 6704 Stock
